Background. Rifampin is recommended in the treatment regimen for staphylococcal prosthetic valve endocarditis (PVE), and for staphylococcal native valve endocarditis (NVE) treated with placement of prosthetic material at surgery. The evidence base for this is scant, and some clinicians opt to forgo rifampin. The purpose of this study was to examine if treatment with rifampin in patients with surgically-treated staphylococcal infective endocarditis (IE) results in better outcomes.
Methods. Patients operated for staphylococcal IE from April 1, 2008 to July 1, 2012 were identified from our institution's IE registry. Treatment was defined as at least 3 days of rifampin post-op. The propensity to receive rifampin was calculated in a model that included NVE vs PVE, Staphylococcus species, left side involvement, invasive disease (extending beyond annulus), positive valve culture, past history of IE, presence of a pacemaker/defibrillator, end-stage renal disease, hepatitis C, and concomitant medications that could interact with rifampin. Cox proportional hazards regression was used to compare a composite outcome of death or reoperation for IE, between patients treated and not treated with rifampin, adjusted for age, sex and propensity to receive rifampin.
Results. 189 patients were identified. Mean age was 56 years, 66% were male, 50% had PVE, 60% had S. aureus or lugdunensis infection, 89% had left side involvement, and 57% had invasive disease. 51 (27%) received at least 3 days of rifampin post-op. The median time to event was 979 days (IQR 191 -1918) . Rifampin treatment was associated with PVE (OR 2.93, p 0.001), left side involvement (OR 3.91, p 0.04), invasive disease (OR 2.26, p 0.02), and concomitant potentially interacting medications (OR 2.13, p 0.04). Patients treated with rifampin had a similar hazard of death or reoperation for IE as those not treated (HR 1.09, 95% CI 0.63 -1.83), after adjusting for age, sex and propensity to receive rifampin. Results were similar when treatment was defined as at least one dose of rifampin, any pre-op rifampin, or rifampin at hospital discharge.
Conclusion. Among patients with surgically treated staphylococcal IE there was insufficient evidence to claim a reoperation-free survival benefit from treatment with rifampin.
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